Cargando…
Lactoferrin and lysozyme to reduce environmental enteric dysfunction and stunting in Malawian children: study protocol for a randomized controlled trial
BACKGROUND: Chronic childhood malnutrition, as manifested by stunted linear growth, remains a persistent barrier to optimal child growth and societal development. Environmental enteric dysfunction (EED) is a significant underlying factor in the causal pathway to stunting, delayed cognitive developme...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674751/ https://www.ncbi.nlm.nih.gov/pubmed/29110675 http://dx.doi.org/10.1186/s13063-017-2278-8 |
_version_ | 1783276842059300864 |
---|---|
author | Cheng, William D. Wold, Karl J. Benzoni, Nicole S. Thakwalakwa, Chrissie Maleta, Kenneth M. Manary, Mark J. Trehan, Indi |
author_facet | Cheng, William D. Wold, Karl J. Benzoni, Nicole S. Thakwalakwa, Chrissie Maleta, Kenneth M. Manary, Mark J. Trehan, Indi |
author_sort | Cheng, William D. |
collection | PubMed |
description | BACKGROUND: Chronic childhood malnutrition, as manifested by stunted linear growth, remains a persistent barrier to optimal child growth and societal development. Environmental enteric dysfunction (EED) is a significant underlying factor in the causal pathway to stunting, delayed cognitive development, and ultimately morbidity and mortality. Effective therapies against EED and stunting are lacking and further clinical trials are warranted to effectively identify and operationalize interventions. METHODS/DESIGN: A prospective randomized placebo-controlled parallel-group randomized controlled trial will be conducted to determine if a daily supplement of lactoferrin and lysozyme, two important proteins found in breast milk, can decrease the burden of EED and stunting in rural Malawian children aged 12–23 months old. The intervention and control groups will have a sample size of 86 subjects each. All field and laboratory researchers will be blinded to the assigned intervention group, as will the subjects and their caregivers. The percentage of ingested lactulose excreted in the urine (Δ%L) after 4 h will be used as the biomarker for EED and linear growth as the measure of chronic malnutrition (stunting). The primary outcomes of interest will be change in Δ%L from baseline to 8 weeks and to 16 weeks. Intention-to-treat analyses will be used. DISCUSSION: A rigorous clinical trial design will be used to assess the biologically plausible use of lactoferrin and lysozyme as dietary supplements for children at high risk for EED. If proven effective, these safe proteins may serve to markedly reduce the burden of childhood malnutrition and improve survival. TRIAL REGISTRATION: Clinicaltrials.gov, NCT02925026. Registered on 4 October 2016. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13063-017-2278-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5674751 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-56747512017-11-15 Lactoferrin and lysozyme to reduce environmental enteric dysfunction and stunting in Malawian children: study protocol for a randomized controlled trial Cheng, William D. Wold, Karl J. Benzoni, Nicole S. Thakwalakwa, Chrissie Maleta, Kenneth M. Manary, Mark J. Trehan, Indi Trials Study Protocol BACKGROUND: Chronic childhood malnutrition, as manifested by stunted linear growth, remains a persistent barrier to optimal child growth and societal development. Environmental enteric dysfunction (EED) is a significant underlying factor in the causal pathway to stunting, delayed cognitive development, and ultimately morbidity and mortality. Effective therapies against EED and stunting are lacking and further clinical trials are warranted to effectively identify and operationalize interventions. METHODS/DESIGN: A prospective randomized placebo-controlled parallel-group randomized controlled trial will be conducted to determine if a daily supplement of lactoferrin and lysozyme, two important proteins found in breast milk, can decrease the burden of EED and stunting in rural Malawian children aged 12–23 months old. The intervention and control groups will have a sample size of 86 subjects each. All field and laboratory researchers will be blinded to the assigned intervention group, as will the subjects and their caregivers. The percentage of ingested lactulose excreted in the urine (Δ%L) after 4 h will be used as the biomarker for EED and linear growth as the measure of chronic malnutrition (stunting). The primary outcomes of interest will be change in Δ%L from baseline to 8 weeks and to 16 weeks. Intention-to-treat analyses will be used. DISCUSSION: A rigorous clinical trial design will be used to assess the biologically plausible use of lactoferrin and lysozyme as dietary supplements for children at high risk for EED. If proven effective, these safe proteins may serve to markedly reduce the burden of childhood malnutrition and improve survival. TRIAL REGISTRATION: Clinicaltrials.gov, NCT02925026. Registered on 4 October 2016. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13063-017-2278-8) contains supplementary material, which is available to authorized users. BioMed Central 2017-11-06 /pmc/articles/PMC5674751/ /pubmed/29110675 http://dx.doi.org/10.1186/s13063-017-2278-8 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Study Protocol Cheng, William D. Wold, Karl J. Benzoni, Nicole S. Thakwalakwa, Chrissie Maleta, Kenneth M. Manary, Mark J. Trehan, Indi Lactoferrin and lysozyme to reduce environmental enteric dysfunction and stunting in Malawian children: study protocol for a randomized controlled trial |
title | Lactoferrin and lysozyme to reduce environmental enteric dysfunction and stunting in Malawian children: study protocol for a randomized controlled trial |
title_full | Lactoferrin and lysozyme to reduce environmental enteric dysfunction and stunting in Malawian children: study protocol for a randomized controlled trial |
title_fullStr | Lactoferrin and lysozyme to reduce environmental enteric dysfunction and stunting in Malawian children: study protocol for a randomized controlled trial |
title_full_unstemmed | Lactoferrin and lysozyme to reduce environmental enteric dysfunction and stunting in Malawian children: study protocol for a randomized controlled trial |
title_short | Lactoferrin and lysozyme to reduce environmental enteric dysfunction and stunting in Malawian children: study protocol for a randomized controlled trial |
title_sort | lactoferrin and lysozyme to reduce environmental enteric dysfunction and stunting in malawian children: study protocol for a randomized controlled trial |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674751/ https://www.ncbi.nlm.nih.gov/pubmed/29110675 http://dx.doi.org/10.1186/s13063-017-2278-8 |
work_keys_str_mv | AT chengwilliamd lactoferrinandlysozymetoreduceenvironmentalentericdysfunctionandstuntinginmalawianchildrenstudyprotocolforarandomizedcontrolledtrial AT woldkarlj lactoferrinandlysozymetoreduceenvironmentalentericdysfunctionandstuntinginmalawianchildrenstudyprotocolforarandomizedcontrolledtrial AT benzoninicoles lactoferrinandlysozymetoreduceenvironmentalentericdysfunctionandstuntinginmalawianchildrenstudyprotocolforarandomizedcontrolledtrial AT thakwalakwachrissie lactoferrinandlysozymetoreduceenvironmentalentericdysfunctionandstuntinginmalawianchildrenstudyprotocolforarandomizedcontrolledtrial AT maletakennethm lactoferrinandlysozymetoreduceenvironmentalentericdysfunctionandstuntinginmalawianchildrenstudyprotocolforarandomizedcontrolledtrial AT manarymarkj lactoferrinandlysozymetoreduceenvironmentalentericdysfunctionandstuntinginmalawianchildrenstudyprotocolforarandomizedcontrolledtrial AT trehanindi lactoferrinandlysozymetoreduceenvironmentalentericdysfunctionandstuntinginmalawianchildrenstudyprotocolforarandomizedcontrolledtrial |